VOOPOO
20.4.2022 06:10:47 CEST | Business Wire | Press release
VOOPOO, leading vape brand, along with its sister brand ZOVOO, is looking forward to meeting you at the National Convenience Show Birmingham 2022 on April 25-27.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220414005472/en/
The National Convenience Show Birmingham is not only the largest retail show in the UK, but also the most professional world-class event in the world’s retail industry. This year, the event will gather 1,000+ global vendors to share cutting-edge consumer insights and commercial trends, and discuss hot topics such as technology, sustainable development, food hygiene and health, and social media. 90,000+ professional visitors are expected to visit the event.
As the leader of vape technology, VOOPOO and ZOVOO will feature three new products of the year in a 25sqm uniquely-designed booth and showcase new technological breakthroughs and smarter experience in the vape industry. On this occasion, VOOPOO looks forward to establishing connections with more excellent partners, peer brands and users, to jointly develop the market.
ARGUS GT 2, a member of VOOPOO’s high-end ARGUS series and the first MOD product in 2022, will be exhibited at the event. While inheriting the classic style of ARGUS GT, ARGUS GT 2 also provides a fully upgraded professional vape experience, a masculine aesthetic design and an improved collision-proof performance to satisfy massive clouds lovers and those vapers who pursue intensive explosion, high performance and high durability. It is poised to define a new height of user experience.
Powerful TPP vape platform, high power and massive clouds
ARGUS GT 2 is compatible with VOOPOO’s universal TPP vape platform, and with a maximum output power of 200W. The moment the ignition button is pressed, massive clouds will volcanically spew out, bringing users the ultimate enjoyment of taste and the strongest visual pleasure. In addition, with a 200W stable output, users are allowed to enjoy the luxurious experience in a leisurely manner.
Top water, dust and collision-proof body to withstand extreme outdoor scenarios
ARGUS GT 2 has obtained the IP68 rating, the highest rating of protection against water, dust and collision. After thousands of tests, the team for ARGUS GT 2 has created a powerful double-layer waterproof, dust-proof, frost-proof, and collision-proof body that can withstand various extreme outdoor environments like temperatures ranging from minus 20°C to 60°C without affecting its performance. Such a hard and durable ARGUS GT 2 will definitely become the best choice for outdoor vapers.
Innovative volcano crater design to guarantee both massive clouds and leak-proofness
Featured with massive clouds, ARGUS GT 2 comes with the MAAT TANK NEW, which has the unique two-way volcano crater airflow design that can increase the airflow rate by 60% and produce thicker clouds at a higher speed; at the same time, it can better drain the condensed liquid to the isolation section at the bottom, so as to create the ultimate leak-proof experience.
Top GENE.TT 2.0 chip to enable new experience of all-scenario intelligence
ARGUS GT 2 features GENE.TT 2.0 technology and is equipped with an upgraded smart chipset which can automatically match power, and supports multi-mode switching between Smart, RBA, Turbo and TC, allowing vapers to easily control their daily experience. In addition, it adopts a hidden 3A TYPE-C fast charging design, and the charging speed is also improved by 30%. VOOPOO products are rich in color and unique in design. ARGUS GT 2 to be displayed this time is no exception. It will offer five new colors including carbon fiber grey, lime green, and dark blue. This perfect fusion of technology and design will surely bring another surprise to the industry.
As a disruptor in the POD market, ZOVOO will bring DRAGBAR 600s, the first disposable vape with a light bar. The DRAGBAR series have been loved by global users since their launch. The innovative use of ethyl maltol to provide the sweetness in e-liquid can effectively avoid sugar addiction which causes harm to the human body, and are popular among vapers who favor sugar-free and low-sugar e-liquid. What kind of disruptive technology will the DRAGBAR 600s present at the show? In addition to ARGUS GT 2, what new surprises will VOOPOO's other two mysterious new products bring to the industry? Let's wait and see at Booth E20 of National Convenience Show Birmingham 2022 from April 25 to 27!
About VOOPOO
Founded in 2017, VOOPOO has rapidly grown and recognized by vapers from around the world with its DRAG series. VOOPOO is a high-tech enterprise integrating R&D, design, production and brand operation. It has four flagship product series: DRAG, VINCI, ARGUS and V Series, altogether providing consumers with a safe, reliable and diverse all-scenario product ecosystem. Currently, VOOPOO products are sold in more than 70 countries and regions in North America, Europe and Asia. VOOPOO will pursue long-term value and strengthen exchanges and cooperation in technology, brand, and supply chain, and promote the innovation and development of the vape industry. For more information, please visit https://www.voopoo.com/ and follow our Instagram, Facebook and TikTok.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220414005472/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
